Discovery and horizontal follow-up of an autoantibody signature in human prostate cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 8, 2015, Pages 2515-2520

  Mintz, Paul J ^a   Rietz, Anna Cecilia ^b,c   Cardó Vila, Marina ^b,c   Ozawa, Michael G ^a   Dondossola, Eleonora ^a   Do, Kim Anh ^a   Kim, Jeri ^a   Troncoso, Patricia ^a   Logothetis, Christopher J ^a   Sidman, Richard L ^d   Pasqualini, Renata ^b,c   Arap, Wadih ^b,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Cancer biomarker; Peptide library; Phage display; Prostate cancer

Indexed keywords

AUTOANTIBODY; EPITOPE; FETUIN A; TUMOR ANTIGEN; ANTIBODY; PEPTIDE;

ANTIBODY BLOOD LEVEL; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER SCREENING; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; LNCAP CELL LINE; MALE; PHAGE DISPLAY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; AMINO ACID SEQUENCE; CELL SURFACE DISPLAY; CHEMISTRY; COMBINATORIAL CHEMISTRY; DISEASE COURSE; IMMUNOLOGY; METASTASIS; MOLECULAR GENETICS; PATHOLOGY; PEPTIDE MAPPING; PROSTATE TUMOR; TUMOR CELL LINE;

ALPHA-2-HS-GLYCOPROTEIN; AMINO ACID SEQUENCE; ANTIBODIES; ANTIGENS, NEOPLASM; AUTOANTIBODIES; CELL LINE, TUMOR; CELL SURFACE DISPLAY TECHNIQUES; COMBINATORIAL CHEMISTRY TECHNIQUES; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; MALE; MOLECULAR SEQUENCE DATA; NEOPLASM METASTASIS; PEPTIDE MAPPING; PEPTIDES; PROSTATIC NEOPLASMS;

EID: 84923657454     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1500097112     Document Type: Article

References (33)

1. Rubin MA (2008) Targeted therapy of cancer: New roles for pathologists-prostate cancer. Mod Pathol 21(Suppl 2):S44-S55.
2. Brawer MK, et al. (1992) Screening for prostatic carcinoma with prostate specific antigen. J Urol 147(3 Pt 2):841-845.
3. Schover LR, et al. (2002) The use of treatments for erectile dysfunction among survivors of prostate carcinoma. Cancer 95(11):2397-2407.
4. Madrid FF, Maroun MC (2011) Serologic laboratory findings in malignancy. Rheum Dis Clin North Am 37(4):507-525.
5. Xie C, et al. (2011) A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases. J Transl Med 9(43):1-11.
6. Bradley SV, et al. (2005) Serum antibodies to huntingtin interacting protein-1: A new blood test for prostate cancer. Cancer Res 65(10):4126-4133.
7. Mintz PJ, et al. (2003) Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol 21(1):57-63.
8. Vidal CI, et al. (2004) An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients. Oncogene 23(55):8859-8867.
9. Arap MA, et al. (2004) Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell 6(3):275-284.
10. Chen G, et al. (2007) Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma. Cancer Res 67(7):3461-3467.
11. Fernández-Madrid F, et al. (2004) Autoantibodies to Annexin XI-A and other autoantigens in the Diagnosis of breast cancer. Cancer Res 64(15):5089-5096.
12. Wang X, et al. (2005) Autoantibody signatures in prostate cancer. N Engl J Med 353(12):1224-1235.
13. Dowling P, et al. (2012) Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. Int J Cancer 131(4):911-923.
14. Petrik V, et al. (2008) Serum alpha 2-HS glycoprotein predicts survival in patients with glioblastoma. Clin Chem 54(4):713-722.
15. Chen J, et al. (2013) Profiling the potential tumor markers of pancreatic ductal adenocarcinoma using 2D-DIGE and MALDI-TOF-MS: Up-regulation of Complement C3 and alpha-2-HS-glycoprotein. Pancreatology 13(3):290-297.
16. Aalinkeel R, et al. (2004) Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells. Cancer Res 64(15):5311-5321.
17. Jia HL, et al. (2007) Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res 13(4):1133-1139.
18. Liu R, et al. (2007) The prognostic role of a gene signature from tumorigenic breastcancer cells. N Engl J Med 356(3):217-226.
19. Zhang R, Pan X, Huang Z, Weber GF, Zhang G (2011) Osteopontin enhances the expression and activity of MMP-2 via the SDF-1/CXCR4 axis in hepatocellular carcinoma cell lines. PLoS ONE 6(8):e23831.
20. Tilli TM, et al. (2012) Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia. Exp Mol Pathol 92(1):13-19.
21. nd (2014) The isoprostanes-25 years later. Biochim Biophys Acta, 10.1016/j.bbalip.2014.10.007.
22. Ammirante M, Shalapour S, Kang Y, Jamieson CA, Karin M (2014) Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts. Proc Natl Acad Sci USA 111(41):14776-14781.
23. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT (2002) Cancer/testis antigens: An expanding family of targets for cancer immunotherapy. Immunol Rev 188(1):22-32.
24. Pedersen KO (1944) Fetuin, a new globulin isolated from serum. Nature 154:575.
25. Triffitt JT, Gebauer U, Ashton BA, Owen ME, Reynolds JJ (1976) Origin of plasma alpha2HS-glycoprotein and its accumulation in bone. Nature 262(5565):226-227.
26. Yang F, et al. (1991) Alpha 2-HS-glycoprotein: Expression in chondrocytes and augmentation of alkaline phosphatase and phospholipase A2 activity. Bone 12(1):7-15.
27. Demetriou M, Binkert C, Sukhu B, Tenenbaum HC, Dennis JW(1996) Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist. J Biol Chem 271(22):12755-12761.
28. Szweras M, et al. (2002) alpha 2-HS glycoprotein/fetuin, a transforming growth factorbeta/ bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling. J Biol Chem 277(22):19991-19997.
29. Schafer C, et al. (2003) The serum protein alpha 2-Heremans-Schmid glycoprotein/ fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 112(3): 357-366.
30. Rittenberg B, et al. (2005) Regulation of BMP-induced ectopic bone formation by Ahsg. J Orthop Res 23(3):653-662.
31. Seto J, et al. (2012) Accelerated growth plate mineralization and foreshortened proximal limb bones in fetuin-A knockout mice. PLoS One 7(10):e47338.
32. Berruti A, et al. (1999) Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem 45(8 Pt 1):1240-1247.
33. Scott JK, Smith GP (1990) Searching for peptide ligands with an epitope library. Science 249(4967):386-390.